Tags: health  medicine  
Channel: Education
Uploaded: December 31, 1969 at 6:59 pm
Author: MedPageToday
Length: 04:27
Rating: 5.00
Views: 164
http://www.medpagetoday.comJ. Leonard Lichtenfeld, M.D., American Cancer SocietyCHICAGO -- For refractory glioblastoma, second-line bevacizumab (Avastin) as monotherapy has been associated with a 28% response rate and an overall survival edge, albeit nonsignificant, over the agent plus irinotecan (Camptosar).